Activation of humoral immunity and eosinophils in neuromyelitis optica

Neurology

Volumn 63, Issue 12, 2004, Pages 2363-2370

  Correale, Jorge ^a   Fiol, Marcela ^a  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; EOTAXIN; EOTAXIN 2; EOTAXIN 3; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 5; INTERLEUKIN 6; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN DEPOSITION; IMMUNOGLOBULIN PRODUCTION; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RELAPSE; REMISSION;

EID: 11144251629     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000148481.80152.BF     Document Type: Article

References (49)

1. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Clinical predictors of a relapsing course and survival. Neurology 2003;60:848-853.
2. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993;34:162-168.
3. O'Riodan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996;60:382-387.
4. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
5. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-1461.
6. Walsh GM. Eosinophil granule proteins and their role in disease. Curr Opin Hematol 2001;8:28-33.
7. Gleich GJ. Mechanism of eosinophil-associated inflammation. J Allergy Clin Immunol 2000;105:651-663.
8. Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol 1999;21:291-295.
9. Badewa AP, Hudson CE, Heiman AS. Regulatory effects of eotaxin, eotaxin-2, and eotaxin-3 on eosinophil degranulation and superoxide anion generation. Exp Biol Med 2002;227:645-651.
10. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin induces eosinophil accumulation in vivo. J Exp Med 1995;182:1169-1174.
11. Caspi RR. IL-12 in autoimmunity. Clin Immunol Immunopathol 1998;88:4-13.
12. Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998;102:671-678.
13. Kerlero de Rosbo N, Honegger P, Lassmann H, Matthieu JM. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin oligodendrocyte glycoprotein. J Neurochem 1990;55:583-587.
14. Von Büdingen HC, Tanuna N, Villoslada P, Ouallet JC, Hauser SL, Genain CP. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J Clin Immunol 2001;21:155-170.
15. Piddlesden SJ, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993;143:555-564.
16. Raine CS, Cannella B, Hauser SL, Genain CP. Demyelination in primate autoimmune encephalomyelitis and multiple sclerosis lesions: a case for antigen specific antibody mediation. Ann Neurol 1999;46:144-160.
17. Sadler RH, Sommer MA, Forno LS, Smith ME. Induction of anti-myelin antibodies in EAE and their possible role in demyelination. J Neurosci Res 1991;30:616-624.
18. Södertröm M, Link H, Xu Z, Fredriksson S. Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. Neurology 1993;43:1215-1222.
19. Adelmann M, Wood J, Benzel I, et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 1995;63:17-27.
20. Correale J, Bassani Molinas M. Time course of T cell responses to MOG and MBP in patients with clinically isolated syndromes. J Neuroimmunol 2003;136:162-171.
21. Sun J, Link H, Olsson T, et al. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 1991;146:1490-1495.
22. Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, Springer MS. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996;183:2349-2354.
23. Rothenberg ME, Mac Lean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997;185:785-790.
24. Miyasato M, Tsuda S, Nakama T, et al. Serum levels of eosinophil cationic protein reflect the state of in vitro degranulation of blood hypodense eosinophils in atopic dermatitis. J Dermatol 1996;23:382-388.
25. Venge P, Bystrom J, Carlson M, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999;29:1172-1186.
26. Cottin V, Deviller P, Tardy F, Cordier JF. Urinary eosinophil-derived neurotoxin/protein X: a simple method assessing eosinophil degranulation in vivo. J Allergy Clin Immunol 1998;101:116-123.
27. Trifilieff A, Fujitani Y, Coyle AJ, Kopf M, Bertrand C. IL-5 deficiency abolishes aspects of airway remodeling in a model of lung inflammation. Clin Exp Allergy 2001;31:934-942.
28. Yoshida Y, Ikuta K, Sugaya H, et al. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity 1996;4:483-494.
29. Luchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
30. Genain CP, Nguyen MH, Letvin NL, et al. Antibody facilitation of multiple sclerosis like lesions in a non human primate. J Clin Invest 1995;96:2966-2974.
31. Linington C, Brandl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-454.
32. Oger J, Kastrukoff L, O'Gorman M, Paty DW. Progressive multiple sclerosis: abnormal immune function in vitro and aberrant correlation with enumeration of lymphocyte subpopulations. J Neuroimmunol 1986;12:37-48.
33. Lolli F, Siracusa G, Amaro MP, et al. Intrathecal synthesis of free immunoglobulin light chains and IgM in initial multiple sclerosis. Acta Neurol Scand 1991;83:239-243.
34. Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003;53:222-226.
35. Nakashima I, Fujihara K, Fujimori J, Narikawa K, Misu T, Itoyama Y. Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica. Neurology 2004;62:144-146.
36. Vandvik B, Natvig JB, Winger D. IgG1 subclass restriction of oligoclonal IgG from cerebrospinal fluid and brain extracts in patients with multiple sclerosis and subacute encephalitides. Scand J Immunol 1976;5:427-436.
37. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme- linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983;65:109-121.
38. Brok HPM, van Meurs M, Blezer E, et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002;169:6554-6563.
39. Metzger DW, Buchanan JM, Collins JT, et al. Enhancement of humoral immunity by interleukin-12. Ann NY Acad Sci 1996;795:100-115.
40. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219-1220.
41. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988;235:449-453.
42. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. N Engl J Med 1984;311:1528-1534.
43. Caputo D, Zaffaroni M, Ghezzi A, Cazzullo CL. Azathioprine reduces intrathecal IgG synthesis in multiple sclerosis. Acta Neurol Scand 1987;75:84-86.
44. Oger JJ, Antel JP, Kuo HH, Arnason BGW. Influence of azathioprine (Imuran) on in vitro immune function in multiple sclerosis. Ann Neurol 1982;11:177-181.
45. Cree B, Lamb S, Chin A, et al. Tolerability and effects of rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS). Neurology 2004;62(suppl 5):A492.
46. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-146.
47. Holers VM. The complement system as a therapeutic target in autoimmunity. Clin Immunol 2003;107:140-151.
48. Izuhara K, Arima K, Yasunaga S. IL-4 and IL-13: their pathological roles in allergic diseases and potential in developing new therapies. Curr Drug Targets Inflamm Allergy 2002;1:263-269.
49. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001;108:S65-71.